Penetration of topically applied tacrolimus into the aqueous humor in Behçet's disease

Annals of Ophthalmology

Volumn 39, Issue 1, 2007, Pages 15-17

  Yalçindaǧ, F Nilüfer ^a,b   Batioǧlu, Figen ^a   Özdemir, Özden ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; BEHCET DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; FEMALE; HUMAN; IRIDOCYCLITIS; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; TREATMENT OUTCOME;

ABSORPTION; ADMINISTRATION, TOPICAL; ADULT; AQUEOUS HUMOR; BEHCET SYNDROME; FEMALE; HUMANS; MALE; TACROLIMUS;

EID: 35648969610     PISSN: 15304086     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02697321     Document Type: Article

References (16)

1. Kino T, Hatanaka H, Hashimoto H, et al. FK-506, a novel immunosuppresant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 1987;40:1249-1255.
2. Kino T, Hatanaka H, Miyata S, et el. FK-506, a novel immunosuppresant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987;40:1256-1265.
3. Sawada S, Suzuki G, Kawase Y, et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987;139:1797-1803.
4. Whitcup SM, Pleyer U, Lai JC, et al. Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol Inflamm 1998;6:51-56.
5. Kawashima H, Fujino Y, Mochizuki M. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1988;29:1265-1271.
6. Hikita N, Chan CC, Whitcnp SM, et al. Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. Curr Eye Res 1995;14:209-214.
7. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Opthalmology 1999;106:723-728.
8. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocular Immunol and Inflamm 1998;6:101-109.
9. Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK506 in refractory uveitis, including Behcet's disease. Transplant Proc 1991;23:3343-3346.
10. Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994;118:723-729.
11. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977-983.
12. Pleyer U, Lutz S, Jusko WJ, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Opthalmol Vis Sci 1993;34:2737-2742.
13. Mills RA, Jones DB, Winkler CR, et al: Topical FK-506 prevents experimental corneal allograt rejection. Cornea 1995;14:157-160.
14. Okada K, Sakata H, Minamoto A, et al: Effect of FK506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. Ophthalmologica 1996;210:175-179.
15. Hikita N, Lopez JS, Chan CC, Mochizuki M, et al: Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci 1997;38:901-909.
16. Fitzgerald P, Hadgraft J, Wilson CG. A gamma-scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles. Int J Pharm 1987;40:81-88.